DRAGONI, GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 922
NA - Nord America 867
AS - Asia 292
OC - Oceania 1
SA - Sud America 1
Totale 2.083
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 864
RU - Federazione Russa 541
IT - Italia 142
SG - Singapore 94
IE - Irlanda 84
HK - Hong Kong 75
PL - Polonia 60
CN - Cina 55
SE - Svezia 49
IN - India 26
JO - Giordania 23
DE - Germania 13
KR - Corea 12
GB - Regno Unito 11
FI - Finlandia 9
FR - Francia 6
JP - Giappone 4
NL - Olanda 3
ES - Italia 2
HN - Honduras 2
VN - Vietnam 2
AM - Armenia 1
AU - Australia 1
BE - Belgio 1
BR - Brasile 1
CA - Canada 1
HR - Croazia 1
Totale 2.083
Salva come PNG Salva come JPEG
Città #
Santa Clara 362
Dublin 84
Singapore 82
Ashburn 60
Warsaw 60
Hong Kong 52
Chandler 37
Moscow 33
Fairfield 32
Florence 22
Altamura 20
Lawrence 20
Shanghai 20
Mumbai 17
Woodbridge 17
West Jordan 16
Beijing 14
Cambridge 14
Seattle 14
Boardman 12
Seoul 12
Kent 11
Boston 10
Buffalo 10
New York 10
Princeton 10
Houston 8
London 8
Wilmington 8
Yubileyny 8
Fontebuona 7
Helsinki 7
Los Angeles 6
Munich 6
Turin 6
Ann Arbor 4
Bari 4
Bologna 4
Corigliano Calabro 4
Piombino 4
Prato 4
Pune 4
Radicondoli 4
Romainville 4
San Diego 4
Washington 4
Falls Church 3
Milan 3
Siano 3
Viareggio 3
Barcelona 2
Bergamo 2
Caccuri 2
Cagliari 2
Castelli Calepio 2
Cerro al Volturno 2
Cranford 2
Dong Ket 2
Farra di Soligo 2
La Ceiba 2
Lappeenranta 2
Medford 2
Montepulciano 2
Naples 2
New Delhi 2
Norwalk 2
Paris 2
Perugia 2
Sarcedo 2
Scandicci 2
Seelow 2
Wakefield 2
Aci Catena 1
Acton 1
Americana 1
Bremen 1
Brussels 1
Cesena 1
Chennai 1
Corciano 1
Core 1
Cornaredo 1
Guangzhou 1
Gurugram 1
Hounslow 1
La Spezia 1
Longyan 1
Pasadena 1
Pescara 1
Phoenix 1
Pieve 1
Pisa 1
Redwood City 1
Rome 1
Romola 1
San Mateo 1
Shenzhen 1
Stirling 1
Tokyo 1
Toronto 1
Totale 1.243
Salva come PNG Salva come JPEG
Nome #
NUCLEAR ORPHAN RECEPTOR COUP-TF2 INCREASED THE RESISTANCE TO ANIKOISIS AND THE METASTATIC POTENTIAL IN HEPATOCELLULAR CARCINOMA 176
CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib 95
GLIM Criteria for Malnutrition in Surgical IBD Patients: A Pilot Study 93
Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes 91
Non-small-bowel lesions identification by capsule endoscopy: A single centre retrospective study 89
Effect of long-lasting nutritional prehabilitation on postoperative outcome in elective surgery for IBD 88
Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centers 71
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 71
Understanding fatigue in primary biliary cholangitis: From pathophysiology to treatment perspectives 69
Nutritional adequacy in surgical IBD patients 67
Pregnancy outcomes in inflammatory bowel disease: Data from a large cohort survey 66
Practical insights into chronic management of hepatic Wilson's disease 64
Relationship between nutritional screening tools and glim in complicated IBD requiring surgery 64
RuvBL1 haploinsufficiency improves mTOR-driven NASH-HCC development in mice 61
Higher volume growth rate is associated with development of worrisome features in patients with branch duct-intraductal papillary mucinous neoplasms 59
Isoforms of the orphan nuclear receptor COUP-TFII differentially modulate pancreatic cancer progression 58
Is the age at surgery in Crohn's disease clinically relevant? Differences and peculiarities: a wide single centre experience after long-term follow-up 58
Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study 58
Metabolic disorders across hepatocellular carcinoma in Italy 56
Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease 56
RUVBL1 correlates with chaperones expression in HCC and its activity is required for HSF1-mediated stress response 54
Main factors influencing long-term outcomes of liver transplantation in 2022 49
T.03.4 SPHINGOSINES, COUP-TFII AND PANCREATIC CANCER 48
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 48
Applicability of the International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) to ulcerative colitis: a preliminary study 48
Schistosomiasis in non-endemic areas: Italian consensus recommendations for screening, diagnosis and management by the Italian Society of Tropical Medicine and Global Health (SIMET), endorsed by the Committee for the Study of Parasitology of the Italian Association of Clinical Microbiologists (CoSP-AMCLI), the Italian Society of Parasitology (SoIPa), the Italian Society of Gastroenterology and Digestive Endoscopy (SIGE), the Italian Society of Gynaecology and Obstetrics (SIGO), the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV), the Italian Society of General Medicine and Primary Care (SIMG), the Italian Society of Infectious and Tropical Diseases (SIMIT), the Italian Society of Pediatrics (SIP), the Italian Society of Paediatric Infectious Diseases (SITIP), the Italian Society of Urology (SIU) 44
Targeting the AAA+ ATPase RuvBL1 reduces mTOR-driven NASH-HCC development in mice 43
RuvBL1 haploinsufficiency promotes hepatic lipid catabolism hampering NASH-HCC progression in mice 43
Correlation of Ultrasound Scores with Endoscopic Activity in Crohn's Disease: A Prospective Exploratory Study 37
Branch duct-intraductal papillary mucinous neoplasms (BD-IPMNs): an MRI-based radiomic model to determine the malignant degeneration potential 36
Gastric Antral Vascular Ectasia (GAVE) a case report, review of the literature and update of techniques 35
Targeting RuvBL1 reduces mTOR-driven NASH-HCC progression in conditional PTEN-KO mice 35
OC.05.6: TARGETING RUVBL1 REDUCES MTOR-DRIVEN NASH-HCC DEVELOPMENT IN MICE 34
MiRNA-Based Therapies for the Treatment of Inflammatory Bowel Disease: What Are We Still Missing? 30
Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches? 29
Totale 2.123
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.499
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.499
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202044 0 0 0 0 9 5 4 8 4 5 6 3
2020/2021109 3 16 7 17 4 3 7 10 15 16 5 6
2021/202272 1 6 7 1 2 7 0 4 7 6 10 21
2022/2023350 14 50 15 7 27 64 52 23 49 23 22 4
2023/2024365 8 26 29 18 24 48 22 71 10 56 35 18
2024/20251.162 73 193 106 319 471 0 0 0 0 0 0 0
Totale 2.123